Medscape

FDA OKs New Formulation of SMA Gene Therapy Itvisma

Itvisma contains the active ingredient in Zolgensma approved in 2019 for children younger than 2 years but is reformulated ...

Cure SMA Welcomes Broad FDA Approval of Itvisma(TM) for Spinal Muscular Atrophy, Reinforces Commitment to Patient Access and Support

SCHAUMBURG, Ill., Nov. 26, 2025 /PRNewswire/ -- Cure SMA, the leading nonprofit organization dedicated to supporting those impacted by spinal muscular atrophy (SMA), welcomes the FDA approval of ...
pharmaphorum

Novartis' SMA gene therapy cleared for wider use in US

The new intrathecal formulation means the one-shot gene therapy is now available to all SMA patients, regardless of their age ...

SC to govt: Consider law to curb ridiculing of disabled

The Supreme Court suggested a law similar to the SC/ST Act to protect differently-abled individuals from ridicule. While the ...
Zacks.com on MSN

FDA Greenlights Novartis' Gene Replacement Treatment for SMA

Novartis secures FDA approval for Itvisma, a one-time gene therapy designed to boost motor function across a broad SMA ...

FDA OKs Novartis SMA Treatment As First Gene Therapy Option For Kids, Teens And Adults

Novartis wins FDA approval for Itvisma, a one-time gene therapy offering broader SMA treatment with sustained motor function ...
Oneindia

SC Rebukes Samay Raina, Urges Him to Use Platform to Honour SMA Warriors

Comic Samay Raina faced the Supreme Court's ire for jokes about Spinal Muscular Atrophy (SMA) sufferers. The court suggested ...
Fierce Pharma

Novartis scores FDA approval for new version of SMA gene therapy, prices at $2.59M

Novartis is pricing Itvisma at a wholesale acquisition cost of $2.59 million, a company spokesperson told Fierce Pharma. At ...
LiveLaw

Delhi High Court Directs Judge To Undergo Training In Matrimonial Laws Citing 'Troubling Lack Of Legal Understanding'

The Delhi High Court has directed a family court judge to undergo an “appropriate and comprehensive refresher training program” in matrimonial laws, citing serious misapplication of law by ...

FDA approves Novartis’ Itvisma, first gene therapy for SMA patients 2 and older

Novartis ( NVS) on Monday said that the U.S. FDA has approved Itvisma for the treatment of children two years and older, ...

Novartis receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA)

Ad hoc announcement pursuant to Art. 53 LR Itvisma (onasemnogene abeparvovec-brve) demonstrated improved motor function and stabilization in patients regardless of SMA treatment history in Phase III ...

Novartis receives FDA approval for Itvisma(R), the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA)

ITVISMA is a prescription gene therapy used to treat adults and children 2 years of age and older with spinal muscular atrophy (SMA). ITVISMA is given as a one-time intrathecal injection. What is the ...